SERES THERAPEUTICS, INC. (NASDAQ:MCRB) Files An 8-K Submission of Matters to a Vote of Security HoldersItem 5.07.
On June26, 2018, Seres Therapeutics, Inc. (the “Company”) held its Annual Meeting of Stockholders. A total of 38,498,469 shares of common stock were present in person or represented by proxy at the meeting, representing approximately 94.7percent of the Company’s outstanding common stock as of the April27, 2018 record date. The following are the voting results for the proposals considered and voted upon at the meeting, all of which were described in the Company’s Definitive Proxy Statement filed with the Securities and Exchange Commission on April30, 2018.
Item 1 — Election of three ClassIII directors to serve until the 2021 Annual Meeting of Stockholders, and until their respective successors have been duly elected and qualified.
| NOMINEE | VotesFOR | VotesWITHHELD | BrokerNon-Votes |
|
NoubarB.Afeyan,Ph.D. |
31,689,669 | 1,348,844 | 5,459,956 |
|
GrégoryBehar |
32,022,317 | 1,016,196 | 5,459,956 |
|
KurtC.Graves |
23,192,033 | 9,846,480 | 5,459,956 |
Item 2 — Ratification of the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the year ending December31, 2018.
| VotesFOR | VotesAGAINST | VotesABSTAINED | BrokerNon-Votes |
|
38,446,403 |
48,636 | 3,430 |
Based on the foregoing votes, Noubar B. Afeyan, Ph.D., Grégory Behar, and Kurt C. Graves were elected as ClassIII directors and Item 2 was approved.
About SERES THERAPEUTICS, INC. (NASDAQ:MCRB)
Seres Therapeutics, Inc. is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. SER-109 is its lead product candidate, which is designed to prevent further recurrences of Clostridium difficile infection (CDI). The Company is developing additional product candidates, including SER-262 to prevent an initial recurrence of primary CDI, SER-287 to treat inflammatory bowel disease (IBD), including ulcerative colitis, and SER-155 to treat enteric bacterial pathogens. The Company is also conducting research on metabolic diseases, such as early-stage, non-insulin dependent diabetes; obesity and metabolic syndrome; other inflammatory diseases; cancer chemotherapy and immune suppression, and rare genetic diseases.
